BACKGROUND: The aim of this study was to compare outcomes in patients with synchronous and metachronous colorectal liver metastases, with special emphasis on prognostic determinants. STUDY DESIGN: We analyzed prospectively collected data on 101 patients with synchronous metastases (group A) who were treated surgically during the time period from April 1998 to December 2006 in regard to overall and disease-free survival, impact of chemotherapy, as well as several serum parameters. A group of patients with metachronous colorectal liver metastases (group B) was considered for baseline comparison. RESULTS: Twenty-three patients in group A received only an explorative laparotomy. Surgical treatment included right hepatectomy (n = 7), left hepatectomy (n = 5), right trisectionectomy (n = 10), left trisectionectomy (n = 1), left lateral resection (n = 11), and sectionectomy (n = 44). Thirty-day mortality was 3%. Morbidity was observed in 10% of the patients. One-, 3-, and 5-year overall survival rates for synchronous metastases were 86%, 68%, and 47%, respectively. The corresponding rates for metachronous metastases were 94%, 68%, and 39% (p > 0.05). Disease free survival was 74%, 42%, and 33% in group A versus 84%, 62%, and 13% in group B (p = 0.28). There was no difference in survival between patients receiving neoadjuvant chemotherapy and no chemotherapy (p > 0.05). Out of all serum parameters, carcinoembryonic antigen levels were a negative predictor for overall and disease-free survival only. CONCLUSIONS: Patients with synchronous colorectal liver metastases had a similar 5-year overall and disease-free survival, which corresponds to patients with metachronous metastases. The impact of neoadjuvant chemotherapy in patients with synchronous metastases needs to be further clarified.
BACKGROUND: The aim of this study was to compare outcomes in patients with synchronous and metachronous colorectal liver metastases, with special emphasis on prognostic determinants. STUDY DESIGN: We analyzed prospectively collected data on 101 patients with synchronous metastases (group A) who were treated surgically during the time period from April 1998 to December 2006 in regard to overall and disease-free survival, impact of chemotherapy, as well as several serum parameters. A group of patients with metachronous colorectal liver metastases (group B) was considered for baseline comparison. RESULTS: Twenty-three patients in group A received only an explorative laparotomy. Surgical treatment included right hepatectomy (n = 7), left hepatectomy (n = 5), right trisectionectomy (n = 10), left trisectionectomy (n = 1), left lateral resection (n = 11), and sectionectomy (n = 44). Thirty-day mortality was 3%. Morbidity was observed in 10% of the patients. One-, 3-, and 5-year overall survival rates for synchronous metastases were 86%, 68%, and 47%, respectively. The corresponding rates for metachronous metastases were 94%, 68%, and 39% (p > 0.05). Disease free survival was 74%, 42%, and 33% in group A versus 84%, 62%, and 13% in group B (p = 0.28). There was no difference in survival between patients receiving neoadjuvant chemotherapy and no chemotherapy (p > 0.05). Out of all serum parameters, carcinoembryonic antigen levels were a negative predictor for overall and disease-free survival only. CONCLUSIONS:Patients with synchronous colorectal liver metastases had a similar 5-year overall and disease-free survival, which corresponds to patients with metachronous metastases. The impact of neoadjuvant chemotherapy in patients with synchronous metastases needs to be further clarified.
Authors: Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: C J Wray; A M Lowy; J B Mathews; S Park; K A Choe; D W Hanto; L E James; D A Soldano; S A Ahmad Journal: Ann Surg Oncol Date: 2005-03-29 Impact factor: 5.344
Authors: Robert Martin; Philip Paty; Yuman Fong; Andrew Grace; Alfred Cohen; Ronald DeMatteo; William Jarnagin; Leslie Blumgart Journal: J Am Coll Surg Date: 2003-08 Impact factor: 6.113
Authors: Dhanwant Gomez; Abed M Zaitoun; Antonella De Rosa; Sina Hossaini; Ian J Beckingham; Adam Brooks; Iain C Cameron Journal: HPB (Oxford) Date: 2014-03-12 Impact factor: 3.647
Authors: Eddie K Abdalla; Todd W Bauer; Yun S Chun; Michael D'Angelica; David A Kooby; William R Jarnagin Journal: HPB (Oxford) Date: 2013-02 Impact factor: 3.647
Authors: Maximilian von Heesen; Jochen Schuld; Jens Sperling; Frank Grünhage; Frank Lammert; Sven Richter; Martin K Schilling; Otto Kollmar Journal: Langenbecks Arch Surg Date: 2011-11-17 Impact factor: 3.445
Authors: Osama H Hamed; Neil H Bhayani; Gail Ortenzi; Jussuf T Kaifi; Eric T Kimchi; Kevin F Staveley-O'Carroll; Niraj J Gusani Journal: HPB (Oxford) Date: 2012-12-27 Impact factor: 3.647
Authors: L J M Mekenkamp; M Koopman; S Teerenstra; J H J M van Krieken; L Mol; I D Nagtegaal; C J A Punt Journal: Br J Cancer Date: 2010-06-15 Impact factor: 7.640
Authors: Andreas Andreou; Scott Kopetz; Dipen M Maru; Su S Chen; Giuseppe Zimmitti; Antoine Brouquet; Junichi Shindoh; Steven A Curley; Christopher Garrett; Michael J Overman; Thomas A Aloia; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2012-10 Impact factor: 12.969